Sponsor intelligence · OTHER
Clinical trials sponsored by
Tianjin Medical University Cancer Institute And Hospital.
Real, source-linked trial activity for Tianjin Medical University Cancer Institute And Hospital: 9 tracked trials, by phase and status, newest first. New trials = pipeline expansion = CRO, site, and reagent demand.
✔ Verified against the public NIH RePORTER & ClinicalTrials.gov records as of Nov 3, 2026. Source-linked, daily-refreshed.
PHASE2 6NA 2N/A 1
Newest Tianjin Medical University Cancer Institute And Hospital trials
| Posted | Trial | Phase | Status | |
|---|---|---|---|---|
| 2d ago | Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive- | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 6d ago | Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer | NA | RECRUITING | ↗ |
| 27d ago | Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reco | NA | NOT_YET_RECRUITING | ↗ |
| 36d ago | FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatm | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 47d ago | Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 51d ago | Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Pat | N/A | RECRUITING | ↗ |
| 51d ago | SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripal | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 62d ago | Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 62d ago | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Tr | Ph 2 | RECRUITING | ↗ |
Get this lane pushed to you the day a new grant or trial lands
Free email digest + a daily new-funding feed (JSON / MCP / webhook) of newly-awarded NIH grants and newly-registered clinical trials for Tianjin Medical University Cancer Institute And Hospital (trial sponsor). Watch institutions, PIs, sponsors, and topics. Newly-funded labs = new buyers, today.